BSE & NSE
16 Dec - 20 Dec '21
₹265 - ₹274
With an emphasis on research and development, Supriya LifeSciences is one of the leading Indian manufacturers and suppliers of Active Pharmaceutical Ingredients. It offers speciality offerings of 38 APIs centered on various categories such as antihistamine, analgesic, anesthetic, vitamin, anti-asthmatic, and antiallergic by the end of October 21.
They have consistently been the top exporter of Chlorpheniramine Maletas and Ketamine Hydrochloride from India, accounting for 45 to 50 percent and 60 to 65 percent of total API exports from India from 2017 to 2021, respectively.
In terms of volume, Supriya LifeSciences is the largest exporter of salbutamol sulfate in India, accounting for 31% of API exports from India in 2021. Its pharmaceutical business is divided into domestic and international sales. Its products are sold to 1,296 clients in 86 countries through 346 distributors.
Here are a few advantages to investing with this company.
The firm is one of India's most well-known API manufacturers.
Its products are exported to over 86 countries due to its specific and diverse market. Due to its de-risked business strategy, the company has superior research and development capabilities as well as a good financial track record.
In the last three years, the company has experienced strong revenue growth.
In the last three years, the company's margins have dramatically improved.
The company’s entire assets, revenues, and profits for the last three years are represented here.
The following are some key dates to remember for Supriya LifeSciences' initial public offering:
The company has a large scale and a leadership position in the industry's main and specialty products. The firm focuses on advanced manufacturing as well as research and development. Supriya Lifescience has a professional management team with extensive expertise and trained operational people.
A complicated set of rules governs their industry. Any production or quality control problems could tarnish the reputation and expose the company to legal action or other liabilities, affecting their financial performance. The sale of specific products accounts for a significant portion of their earnings.
The corporation uses an integrated business model. With a presence in around 86 countries, it is a global player.
Their lenders have imposed some restrictions on them as part of their financial arrangements. Their inability to compete successfully in the pharmaceutical sector could hurt their firm. Existing technologies may become obsolete as a result of technological breakthroughs, necessitating major capital inputs.
A large corporation with a leadership position in important and specialized products.
It has a business model that is backward integrated.
Its revenues are geographically diverse, with a global presence in 86 countries.
Advanced manufacturing and research and development capabilities are available at the company.
Due to its de-risked business style, the company produces consistently solid financial results.
It has a senior management team with years of experience and qualified operational personnel.
You can apply for the Supriya Lifescience Ltd. IPO in these ways:
Link your personal bank A/C to a trusted UPI ID and map it with your TradeSmart account. Now, proceed further to book your IPO. On acceptance of the mandate, the bid amount will get blocked in your bank account Learn more.
When will Supriya Lifescience's initial public offering (IPO) begin?
The Supriya Lifescience initial public offering (IPO) will begin on December 16, 2021, and end on December 20, 2021.
What is the Supriya Lifescience IPO lot size?
The minimum order quantity for the Supriya Lifescience IPO is 54 shares, and the market lot size is 13.
What percentage of the IPO is allotted to each investment group?
QIB - 75% of the available shares. Retail - 10% of the available share must be sold to the general public. NII / HNI - 15% of the offered shares for NII / HNI.
What is the minimum subscription amount for this IPO?
Investors must apply for 54 shares at the lowest price range of INR 265 per share, which equals INR 14,310. Similarly, the minimum amount to be applied on the upper pricing band is INR 274 = INR 14,796.
Is it advantageous or disadvantageous in terms of investment?
Investing in a firm with a solid financial track record is usually a good idea. In the last 3.5 years, this company has had significant revenue growth. In recent years, the company's profits have increased significantly.
What is the current status of Supriya LifeScience's IPO GMP?
GMP stands for the premium at which shares trade in the offline market. Because it is an unorganised market, this is merely an indicator of the IPO price. Supriya LifeScience IPO GMP is not available because no trades are currently taking place.